Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Ringside For Zarxio At Supreme Court: Biosimilar Stakeholders Line Up

Executive Summary

High court set to determine timing of biosimilar marketing and how parties handle patent disputes in Sandoz v. Amgen. Stakeholders say the outcome will impact innovation, access to biosimilars and future litigation.

Advertisement

Related Content

FDA's Worst Case Scenario: Supreme Court Might Defer To It On Biosimilars
Biosimilars Podcast: What To Expect When Supreme Court Hears Amgen vs. Sandoz
Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts
A Look At Payers' Early Game Plans For Driving Biosimilar Use
Biosimilar Litigation: Genentech Avastin Suit Tossed; Janssen Remicade Case Uncertain
Biosimilar sponsors can avoid 'patent dance' in US, but innovators win extra exclusivity

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel